JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.12, pp.2145-2151, 2012 (SCI-Expanded)
Article / Article
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Trastuzumab, Adjuvant therapy, Breast cancer, HER2, PLUS ADJUVANT CHEMOTHERAPY, DOCETAXEL, ONCOGENE
Gazi University Affiliated:
Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.